血清HBV RNA检测的临床价值

刘瑞霞; 潘修成; 耿建

doi:10.3969/j.issn.1001-5256.2017.11.032

血清HBV RNA检测的临床价值

DOI: 10.3969/j.issn.1001-5256.2017.11.032

徐州医科大学附属医院感染科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2236
- HTML全文浏览量: 46
- PDF下载量: 446
- 被引次数: 0
出版历程
- 收稿日期: 2017-04-27
- 出版日期: 2017-11-20

Clinical value of serum HBV RNA

Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University

摘要

摘要: 目前虽有多种用于评价抗HBV疗效的指标,但其总体准确性和敏感性仍不高,仍需要新的评估指标用于指导临床。近几年研究发现HBV RNA可能是一种具有潜在用于临床检测价值的新指标。就HBV RNA的基本概念、检测方法及在临床诊断中的价值等方面做一综述。
- 肝炎病毒,乙型 /
- RNA,病毒 /
- 生物学标记 /
- 综述
Abstract: Although there are various indicators for evaluating the effect of anti-HBV therapy, they have low accuracy and sensitivity.New indicators are still needed to guide clinical practice.Recent studies have found that HBV RNA might be a new potential indicator for clinical detection.This article reviews the basic concepts of HBV RNA, related detection methods, and the value of HBV RNA in clinical diagnosis.
- hepatitis B virus /
- RNA, viral /
- biological markers /
- review

HTML全文

参考文献(36)

[1]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[2]MARION PL, WINTERS MA, SALAZAR FH, et al.Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.Antimicrob[J].Agents Chemother, 2002, 46 (1) :82-88.

[3]WOLTERS LM, HANSEN BE, NIESTERS HG, et al.Viral dynamics in chronic hepatitis B patients during lamivudine therapy[J].Liver, 2002, 22 (2) :121-126.

[4]LUO KX.Hepatitis B basic biology and clinical science[M].3rd ed.Beijing:People's Medical Publishing House, 2006:54-58. (in Chinese) 骆抗先.乙型肝炎基础和临床[M].3版.北京:人民卫生出版社, 2006:54-58.

[5]KOCK J, THEILMANN L, GALLE P, et al.Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus[J].Hepatology, 1996, 23 (3) :405-413.

[6]TANAKA E, ROKUHARA A, MATSUMOTO A, et al.Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy[J].Gastroenterol, 2006, 41 (8) :785-790.

[7]SU Q, WANG SF, CHANG TE, et al.Circulating hepatitis B virus nucleic acids in chronic infection:represantation of differently polyadenylated viral transcripts during progression to nonreplicative stages[J].Clin Cancer, 2001, 7 (7) :2005-2015.

[8]Chinese Journal of Hepatology, Journal of Clinical Hepatology, Chinese Hepatology.Potential clinical significance of serum HBV RNAvirus-like particles[J].J Clin Hepatol, 2016, 32 (9) :1635-1636. (in Chinese) 中华肝脏病杂志, 临床肝胆病杂志, 《肝脏》杂志.HBV RNA病毒样颗粒的潜在临床意义[J].临床肝胆病杂志, 2016, 32 (9) :1635-1636.

[9]HUI CK, CHEUNG WW, ZHANG HY, et al.Kinetics and risk of denovo hepatitis B infection in HBs Ag-negative patients undergoing cytotoxic chemotherapy[J].Gastroenterology, 2006, 131 (1) :59-68.

[10]LU FM, REN H, KUMAR GR, et al.Serum hepatitis B virus RNAis encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J].J Hepatol, 2016, 65 (4) :700-710.

[11]WANG J, DU M, HUANG H, et al.Reply to:“Serum HBVpgRNA as a clinical marker for ccc DNA activity”[J].J Hepatol, 2016, 66 (2) :462-463.

[12]GIERSCH K, All WEISS L, VOLZ T, et al.Serum HBV pgRNA as a clinical marker for ccc DNA activity[J].J Hepatol, 2017, 66 (2) :460-462.

[13]LU FM, WANG J, NIU JQ, et al.Serum HBV RNA can reflect the activity of intrahepatic ccc DNA[C].26th Annual Conference of APASL.Shanghai, 2017.

[14]TSUGE M, MURAKAMI E, IMAMURA M, et al.Serum HBVRNA and HBe Ag are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients[J].Gastroenterol, 2013, 48 (10) :1188-1204.

[15]BARTENS A, HOFMANN J, EDELMANN A, et al.Serum hepatitis Bvirus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J].Hepatology, 2015, 61 (1) :66-76.

[16]BERG T, WACKER J, BREHM M, et al.HBV RNA and HBVcore-related antigen (HBcr Ag) are early serum markers for HBe Ag seroconversion in treatment experienced patients receiving tenofovir disoproxil fumarate (TDF) [C].67th annual meeting of the American Association for the Study of Liver Diseases.Boston, 2016.

[17]Chinese Society of Hepatology, Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :I-XVI. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010版) [J].临床肝胆病杂志, 2011, 27 (1) :I-XVI.

[18]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.

[19]ZHAO YN, LI H.Advances in research on anti HBV target[J].Int J Virol, 2017, 24 (3) :197-200. (in Chinese) 赵亚楠, 李红.抗乙型肝炎病毒靶点研究进展[J].国际病毒学杂志, 2017, 24 (3) :197-200.

[20]SCHALM SW, HEATHCOTE J, CIANCIARA J, et al.Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection:a randomized trial[J].Gut, 2000, 46 (4) :562-568.

[21]SARIN SK, KUMAR M, KUMAR R, et al.Higher efficacy of sequential therapy with interferon-alpha and Lamivudine combination compared to Lamivudine monotherapy in HBe Ag positive chronic hepatitis B patients[J].Am J Gastroenterol, 2005, 100 (11) :2463-2471.

[22]SARIN SK, SOOD A, KUMAR M, et al.Effect of lowering HBVDNA levels by initial antiviral therapy before adding immunodulator on treatment of chronic hepatitis B[J].Am J Gastroenterol, 2007, 102 (1) :96-104.

[23]CHAYAMA K, HUANG YW, HATAKEYAMA T, et al.Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B[J].Antivir Ther, 2010, 15 (2) :177-184.

[24]DIENSTAG JL.Hepatitis B virus infection[J].N Engl J Med, 2008, 359 (14) :1486-1500.

[25]WIELAND SF, GUIDOTTI LG, CHISARI FV, et al.Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice[J].J Virol, 2000, 74 (9) :4165-4173.

[26]DOONG SL, TSAI CH, SCHINAZI RF, et al.Inhibition of the replication of hepatitis B virus in vitro by 2'3'-dideoxy-3'-thiacytidine and related analogues[J].Proc Natl Acad Sci USA, 1991, 88 (19) :8495-8499.

[27]TAKAHASHI S, TSUGE M, HUANG YW, et al.On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy[J].Antiviral Therapy, 2015, 20 (4) :369-375.

[28]JANSEN L, KOOTSTRA NA, van DORTKA, et al.Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos (t) ide analogues[J].Infect Dis, 2016, 213 (2) :224-232.

[29]HAYASHI Y, BAI F, FUKUMOTO T, et al.Quantification of pregenomic RNA and covalently closed circular DNA in hepatitis B virus-related hepatocellular carcinoma[J].Int Hepatol, 2013, 2013:849290.

[30]HIRAGA N, HATAKEYAMA T, NOGUCHI C, et al.Serum HBV RNAis a predictor of early emergence of the YMDD mutant in patients treated with Lamivudine[J].Hepatology, 2007, 45 (5) :1179-1186.

[31]REIJNDERS JG, PERQUIN MJ, ZHANG N, et al.Nucleos (t) ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B[J].Gastroenterology, 2010, 139 (2) :491-498.

[32]CHI H, HANSEN BE, YIM C, et al.Reduced risk of relapse after long-term nucleos (t) ide analogue consolidation therapy for chronic hepatitis B[J].Aliment Pharmacol Ther, 2015, 41 (9) :867-876.

[33]RYU SH, CHUNG YH, CHOI MH, et al.Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBe Ag loss:a prospective study[J].J Hepatol, 2003, 39 (4) :614-619.

[34]WANG Y, THONGSAWAT S, GANE EJ, et al.Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B[J].J Viral Hepat, 2013, 20 (4) :e37-e46.

[35] LU FM, WANG J, REN H, et al.The potential use of serum HBVRNA to guide the functional cure of chronic hepatitis B[J].Chin JHepatol, 2017, 25 (2) :105-110. (in Chinese) 鲁凤民, 王杰, 任红, 等.乙型肝炎病毒RNA病毒样颗粒的发现及其对抗病毒治疗临床实践的潜在影响[J].中华肝脏病杂志, 2017, 25 (2) :105-110.

[36]SEEGERC, MASON WS.Hepatitis B virus biology[J].Microbiol Mol Biol Rev, 2000, 64 (1) :51-68.

施引文献

资源附件(0)

访问统计